Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Vielight Neuro Rx Gamma Active Device

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 1 (1)

Trial Status

Active Not Recruiting1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT02918994Not ApplicableActive Not Recruiting

LearningRx Cognitive Training for Brain Injury

NCT05857124Phase 1CompletedPrimary

A Study Evaluating the Efficacy of the Vielight Neuro RX Gamma in the Treatment of Post COVID-19 Cognitive Impairment

Showing all 2 trials

Research Network

Common Treatments

  • Vielight Neuro Rx Gamma Active Device1
  • Learningrx Cognitive Training1
  • Vielight Neuro Rx Gamma Sham Device1

Active Sponsors

  • Louisiana State University Health Sciences Center Shreveport1
  • Vielight Inc.1
  • Gibson Institute of Cognitive Research1

Top Investigators

Related Conditions

  • Traumatic Brain Injury Tbi1
  • Acquired Brain Injury1

Activity Timeline